Pacific Point Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
Other funds holding LLY
VCM
VPM
Pacific Point Advisors's LLY Position: Q1 2026 in Review
Pacific Point Advisors increased its Eli Lilly (LLY) stake by 0.5% in Q1 2026, buying an estimated $7.1K and bringing the position to 1,420 shares worth $1.31M. The position accounts for 0.69% of the portfolio, ranked #51.
Pacific Point Advisors first reported a position in LLY in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.52M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Pacific Point Advisors held 1,420 shares of Eli Lilly worth $1.31M as of Q1 2026.
- Pacific Point Advisors bought 7 Eli Lilly shares in Q1 2026, an estimated $7.1K.
- Eli Lilly made up 0.69% of Pacific Point Advisors's portfolio in Q1 2026, its #51 holding.
- Pacific Point Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 6 quarters since.
- Pacific Point Advisors's Eli Lilly position peaked at $1.52M in Q4 2025.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Pacific Point Advisors's 13F filing for Q1 2026, filed 4 May 2026.